Arama Sonuçları - Jasgit C. Sachdev

  • Gösterilen 1 - 17 sonuçlar arası kayıtlar. 17
Sonuçları Daraltın
  1. 1
    AKT in cancer: new molecular insights and advances in drug development

    AKT in cancer: new molecular insights and advances in drug development Yazar: Prabhjot S. Mundi, Jasgit C. Sachdev, Carolyn K. McCourt, Kevin Kalinsky

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

    Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Yazar: Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Mitesh J. Borad, Yoon‐Koo Kang, Jay Stoudemire, Stephen M. Smith, Andreas G. Bader, Sinil Kim, David S. Hong

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

    Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours Yazar: Devalingam Mahalingam, Manish R. Patel, Jasgit C. Sachdev, Lowell L. Hart, Niels Halama, Ramesh K. Ramanathan, John Sarantopoulos, Dirk Völkel, Ashraf Youssef, Floris A. de Jong, Apostolia M. Tsimberidou

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

    Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors Yazar: Pamela N. Münster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors Yazar: Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Laurie A. Winter, Christine Reilly, Robert B. Parker, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer, Ramesh K. Ramanathan

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

    Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Yazar: Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Jasgit C. Sachdev, Ronald G. Newbold, Gayle Jameson, Gerald J. Fetterly, Joshua Prey, Stephan G. Klinz, Jaeyeon Kim, Jason E. Cain, Bart S. Hendriks, Daryl C. Drummond, Eliel Bayever, Jonathan B. Fitzgerald

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

    A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours Yazar: Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher, Amita Patnaik, Drew Rasco, R. Donald Harvey, Patricia LoRusso, Jasgit C. Sachdev, Giovanni Abbadessa, Ronald E. Savage, Traci M. Tanaka Hall, Brian Schwartz, Y. Wang, Julia Kazakin, Walid L. Shaib

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

    First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors Yazar: Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna P. Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevin J. Freise, Dimple Modi, Anjla Sood, Jessica E. Hutti, Johannes Wolff, Bert H. O’Neil

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Yazar: Michael L. Maitland, Jasgit C. Sachdev, Manish Sharma, Víctor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal J. Lakhani, Allison Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers

    Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers Yazar: Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Yazar: Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Patrick A. Ott, Sarina A. Piha‐Paul, Philippe L. Bédard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R. Tan

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

    First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin... Yazar: Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Glen J. Weiss, Jasgit C. Sachdev, Manpreet K. Chadha, Maddie Fulk, Samuel Ejadi, James M. Mountz, Michael T. Lotze, Frederico G. S. Toledo, Edward Chu, Michael Jeffers, Carol E. Peña, Chenjing Xia, Stefanie Reif, Isabelle Genvresse, Ramesh K. Ramanathan

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours Yazar: David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim, Andrew Brenner, Keunchil Park, Jae‐Lyun Lee, Tae‐You Kim, SangJoon Shin, Carlos Becerra, Gerald S. Falchook, Jay Stoudemire, Desiree Martin, Kevin Kelnar, Heidi J. Peltier, Vinícius Bonato, Andreas G. Bader, Stephen M. Smith, Sinil Kim, Vincent O’Neill, Muhammad Shaalan Beg

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor

    Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor Yazar: Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Peter J. O’Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

    Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma Yazar: Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal, Monica Mita, John W. Moroney, Robert W. Holloway, Linda Van Le, Jasgit C. Sachdev, Eloise Chapman‐Davis, Gerardo Colón‐Otero, Richard T. Penson, Ursula A. Matulonis, Young Bae Kim, Kathleen N. Moore, Elizabeth M. Swisher, Anniina Färkkilä, Alan D. D’Andrea, Erica Stringer-Reasor, Jing Wang, Nathan Buerstatte, Sujata Arora, Julie R. Graham, Dmitri Bobilev, Bruce J. Dezube, Pamela N. Münster

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Invasive Breast Cancer

    Invasive Breast Cancer Yazar: Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon H. Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt‐Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth Reed, Jasgit C. Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, Richard C. Zellars

    Baskı/Yayın Bilgisi 2011
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Hepatobiliary Cancers

    Hepatobiliary Cancers Yazar: Al B. Benson, Thomas A. Abrams, Edgar Ben‐Josef, Mark Bloomston, Jean F. Botha, Bryan M. Clary, Anne M. Covey, Steven A. Curley, Michael I. D’Angelica, Rene Davila, William D. Ensminger, John F. Gibbs, Daniel Laheru, Mokenge P. Malafa, Jorge A. Marrero, Steven G. Meranze, Sean J. Mulvihill, James O. Park, James Posey, Jasgit C. Sachdev, Riad Salem, Elin R. Sigurdson, Constantinos Sofocleous, Jean‐Nicolas Vauthey, Alan P. Venook, Laura W. Goff, Yun Yen, Andrew X. Zhu

    Baskı/Yayın Bilgisi 2009
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: